Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HCN4 | Q9Y3Q4 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7911834 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| SCHEMBL7436614 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| SCHEMBL31936524 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| SCHEMBL31549 | 1.00 | CYP3A4 (0.43) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| Hydrochloric Acid SCHEMBL30081991 | 0.98 | MAOA (0.42) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| Hydrochloric Acid SCHEMBL9427970 | 0.98 | MAOA (0.42) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| Hydrochloric Acid SCHEMBL384338 | 0.98 | MAOA (0.42) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| Hydrochloric Acid SCHEMBL7274416 | 0.98 | MAOA (0.42) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| SCHEMBL20041776 | 0.92 | HTR2A (0.38) | CYP3A4MAPTHTR2ANQO2MTNR1A | |
| SCHEMBL3163151 | 0.88 | TAAR1 (0.41) | HTR2ANQO2MTNR1AMTNR1BCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097383-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | Cadila Healthcare Limited (IN) | 2009-09-09 | — | — | EP | claimed |
| WO-2008065681-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-06-05 | — | — | WO | claimed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| US-9476071-B2 | Process for the enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]OCTA-1,3,5-triene-7-carboxylic acid and application in the synthesis of ivabradine and salts thereof | LES LABORATOIRES SERVIER (FR) | 2016-10-25 | — | — | US | disclosed |
| EP-2772547-B1 | Method for enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid, and use for the synthesis of ivabradine and the salts thereof | SERVIER LAB (FR) | 2015-07-08 | — | — | EP | disclosed |
| EP-2687506-B1 | Method for enzymatic synthesis of (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-yl) N-methyl methanamine, and use for the synthesis of Ivabradine and the salts thereof | SERVIER LAB (FR) | 2015-06-24 | — | — | EP | disclosed |
| US-9045788-B2 | Process for the enzymatic synthesis of (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) N-methyl methanamine, and application in the synthesis of ivabradine and salts thereof | LES LABORATOIRES SERVIER (FR) | 2015-06-02 | — | — | US | disclosed |
| US-9045788-B2 | Process for the enzymatic synthesis of (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) N-methyl methanamine, and application in the synthesis of ivabradine and salts thereof | LES LABORATOIRES SERVIER (FR) | 2015-06-02 | — | — | US | disclosed |
| US-9045788-B2 | Process for the enzymatic synthesis of (7S)-1-(3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl) N-methyl methanamine, and application in the synthesis of ivabradine and salts thereof | LES LABORATOIRES SERVIER (FR) | 2015-06-02 | — | — | US | disclosed |
| EP-2626428-B1 | Method for enzymatic synthesis of (7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carboxylic acid or the esters thereof, and use for the synthesis of ivabradine and the salts thereof | SERVIER LAB (FR) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014131996-A1 | METHOD FOR THE ENZYMATIC SYNTHESIS OF (7S) 3,4-DIMETHOXYBICYCLO[4.2.0]OCTA-1,3,5-TRIENE 7-CARBOXYLIC ACID AND USE THEREOF IN THE SYNTHESIS OF IVABRADINE AND SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2014-09-04 | — | — | WO | disclosed |
| EP-2241554-A1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2097383-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | Cadila Healthcare Limited (IN) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008065681-A2 | PROCESS FOR PREPARATION OF IVABRADINE HYDROCHLORIDE | CADILA HEALTHCARE LIMITED (IN) | 2008-06-05 | — | — | WO | disclosed |
| EP-1598333-B1 | Process for the preparation of (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid addition salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2006-10-18 | — | — | EP | disclosed |
| US-6982350-B2 | Process for the synthesis of (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane and addition salts thereof, and to the application thereof in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2006-01-03 | — | — | US | disclosed |
| WO-2005123659-A1 | METHOD OF SYNTHESISING (1S)-4,5-DIMETHOXY-1- (METHYLAMINOMETHYL)-BENZOCYCLOBUTANE AND THE ADDITION SALTS THEREOF, AND USE OF SAME FOR THE SYNTHESIS OF IVABRADINE AND THE PHARMACEUTICALLY-ACCEPTABLE ADDITION SALTS THEREOF | LES LABORATOIRES SERVIER (FR) | 2005-12-29 | — | — | WO | disclosed |
| US-20050261376-A1 | PROCESS FOR THE SYNTHESIS OF (IS)-4,5-DIMETHOXY-1-(METHYLAMINOMETHYL)-BENZOCYCLOBUTANE AND ADDITION SALTS THEREOF, AND TO THE APPLICATION THEREOF IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598333-A1 | Process for the preparation of (1S)-4,5-dimethoxy-1-(methylaminomethyl)-benzocyclobutane, acid addition salts thereof and its use for the synthesis of ivabradine and for its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249397-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | CYP3A4 15/4885MAPT 4588/4885HTR2A 1651/4885 |
| US-20050261376-A1 | PROCESS FOR THE SYNTHESIS OF (IS)-4,5-DIMETHOXY-1-(METHYLAMINOMETHYL)-BENZOCYCLOBUTANE AND ADDITION SALTS THEREOF, AND TO THE APPLICATION THEREOF IN THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4B1, CYP4F2, CYP2S1 | CYP3A4 12/4885MAPT 4805/4885HTR2A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.